Humacyte Reports $2.0M 2025 Revenue, Secures $1.475M Saudi Purchase Commitment
Humacyte posted Q4 revenues of $0.5M and full-year $2.0M, including $0.4M in Symvess sales and secured a $1.475M purchase commitment for Saudi Arabia outreach. The firm won US Department of Defense funding, filed an Israeli Marketing Authorization Application and targets top-line V012 Phase 3 hemodialysis results in Q2 2026.
1. Q4 and Full-Year Financial Results
Humacyte recorded total revenues of $0.5 million in Q4 2025 and $2.0 million for the full year, including $0.4 million in fourth-quarter Symvess sales and $1.4 million for the year. Value Analysis Committee approvals rose to 27, and 27 hospitals have placed orders with many submitting reorders.
2. Commercial Expansion and Purchase Commitment
Humacyte secured a minimum $1.475 million purchase commitment to support surgeon education and clinical evaluation of Symvess in the Kingdom of Saudi Arabia. Negotiations are underway with a Saudi entity for a joint venture and commercialization license.
3. Government Funding and Regulatory Filings
The U.S. Department of Defense approved funding for procurement of bioengineered blood vessels to treat traumatic vascular injuries in service personnel. Humacyte also submitted a Marketing Authorization Application to the Israel Ministry of Health for Symvess in arterial trauma repair and is arranging hospital-by-hospital access pending approval.
4. Clinical Pipeline and Upcoming Milestone
The company anticipates top-line interim data from the V012 Phase 3 hemodialysis access study in women in Q2 2026, advancing toward a planned BLA filing in the second half of 2026. Early-stage development includes large-scale manufacturing of coronary tissue engineered vessels for a potential CABG trial later in 2026.